Table 1.
The distribution of genotype frequencies of TLR SNPs in healthy women and those with ovarian cancer. An association of TLR genotype with the occurrence of ovarian cancer related to HPV infection.
| Gene SNP |
Model | Genotype | Genotype Frequencies, n (%) a | Unadjusted | Adjusted b | Adjusted c | ||||
|---|---|---|---|---|---|---|---|---|---|---|
| Controls | Cases | OR (95% CI) | p | OR (95% CI) | p | OR (95% CI) | p | |||
| TLR4 | Codominant | AA | 128 (98.5) | 56 (80.0) | 1.00 | <0.0001 | 1.00 | 0.0005 | 1.00 | 0.0085 |
| rs4986790 | AG | 2 (1.5) | 13 (18.6) | 14.86 (3.24–68.03) | 14.40 (2.99–69.41) | 8.83 (1.54–50.53) | ||||
| GG | 0 (0) | 1 (1.4) | NA (0.00–NA) | 11.77 (0.00–NA) | NA (0.00–NA) | |||||
| Dominant | AA | 128 (98.5) | 56 (80) | 1.00 | <0.0001 | 1.00 | 0.0001 | 1.00 | 0.003 | |
| AG-GG | 2 (1.5) | 14 (20) | 16.00 (3.52–72.76) | 14.40 (2.99–69.41) | 11.03 (2.04–59.72) | |||||
| Recessive | AA-AG | 130 (100) | 69 (98.6) | 1.00 | 0.15 | 1.00 | 1 | 1.00 | 0.075 | |
| GG | 0 (0) | 1 (1.4) | NA (0.00–NA) | 11.30 (0.00–NA) | NA (0.00–NA) | |||||
| Overdominant | AA-GG | 128 (98.5) | 57 (81.4) | 1.00 | <0.0001 | 1.00 | 0.0001 | 1.00 | 0.013 | |
| AG | 2 (1.5) | 13 (18.6) | 14.60 (3.19–66.81) | 14.40 (2.99–69.41) | 8.53 (1.49–48.78) | |||||
| TLR4 | Codominant | CC | 119 (91.54) | 63 (90.0) | 1.00 | 0.35 | 1.00 | 0.87 | 1.00 | 1 |
| rs4986791 | CT | 11 (8.5) | 6 (8.6) | 1.03 (0.36–2.92) | 0.71 (0.19–2.64) | 1.05 (0.28–3.98) | ||||
| TT | 0 (0) | 1 (1.4) | NA (0.00–NA) | 0.00 (0.00–NA) | 0.00 (0.00–NA) | |||||
| Dominant | CC | 119 (91.5) | 63 (90.0) | 1.00 | 0.72 | 1.00 | 0.59 | 1.00 | 0.95 | |
| CT-TT | 11 (8.5) | 7 (10.0) | 1. 20 (0.44–3.25) | 0.71 (0.19–2.64) | 1.05 (0.28–3.98) | |||||
| Recessive | CC-CT | 130 (100) | 69 (98.6) | 1.00 | 0.15 | 1.00 | 1 | 1.00 | 1 | |
| TT | 0 (0) | 1 (1.4) | NA (0.00–NA) | 0.00 (0.00–NA) | 0.00 (0.00–NA) | |||||
| Overdominant | CC-TT | 119 (91.5) | 64 (91.4) | 1.00 | 0.98 | 1.00 | 0.59 | 1.00 | 0.95 | |
| CT | 11 (8.5) | 6 (8.6) | 1.01 (0.36–2.87) | 0.71 (0.19–2.64) | 1.05 (0.28–3.98) | |||||
| TLR9 | Codominant | TT | 35 (28.2) | 15 (22.4) | 1.00 | 0.091 | 1.00 | 0.14 | 1.00 | 0.85 |
| rs187084 | TC | 81 (65.3) | 41 (61.2) | 1.18 (0.58–2.41) | 0.90 (0.41–1.94) | 0.96 (0.40–2.32) | ||||
| CC | 8 (6.5) | 11 (16.4) | 3.21 (1.08–9.57) | 2.69 (0.84–8.66) | 1.46 (0.32–6.64) | |||||
| Dominant | TT | 35 (28.2) | 15 (22.4) | 1.00 | 0.38 | 1.00 | 0.88 | 1.00 | 0.99 | |
| TC-CC | 89 (71.8) | 52 (77.6) | 1.36 (0.68–2.73) | 1.06 (0.50–2.23) | 1.00 (0.42–2.38) | |||||
| Recessive | TT-TC | 116 (93.5) | 56 (83.6) | 1.00 | 0.032 | 1.00 | 0.049 | 1.00 | 0.58 | |
| CC | 8 (6.5) | 11 (16.4) | 2.85 (1.09–7.48) | 2.90 (1.02–8.24) | 1.50 (0.37–6.01) | |||||
| Overdominant | TT-CC | 43 (34.7) | 26 (38.8) | 1.00 | 0.57 | 1.00 | 0.27 | 1.00 | 0.77 | |
| TC | 81 (65.3) | 41 (61.2) | 0.84 (0.45–1.55) | 0.68 (0.35–1.35) | 0.88 (0.40–1.98) | |||||
a Values are the number of examined healthy women (controls) and those with OC (cases). (%); b Adjusted analysis was carried out for HPV16 DNA copy number in whole-blood samples; c Adjusted analysis was carried out for HPV18 DNA copy number in whole-blood samples; OR: odds ratio; 95% CI: 95% confidence interval; p, logistic regression model; NA: not available; PB, The significance level after Bonferroni’s correction for multiple testing was 0.017 (raw p-value/3).